- Home
- ODD vs RNA Comparison
ODD vs RNA Comparison
Compare ODD & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | RNA |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODD | RNA |
|---|---|---|
| Price | $35.29 | $72.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $66.73 | ★ $69.26 |
| AVG Volume (30 Days) | 794.1K | ★ 1.9M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $780,758,000.00 | $20,868,000.00 |
| Revenue This Year | $26.15 | $57.30 |
| Revenue Next Year | $20.55 | $28.41 |
| P/E Ratio | $19.72 | ★ N/A |
| Revenue Growth | 25.80 | ★ 106.27 |
| 52 Week Low | $33.06 | $21.51 |
| 52 Week High | $79.18 | $72.70 |
Technical Indicators
Market Signals| Indicator | ODD | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 72.72 |
| Support Level | $33.06 | $72.23 |
| Resistance Level | $35.85 | $72.70 |
| Average True Range (ATR) | 1.56 | 0.17 |
| MACD | -0.41 | -0.14 |
| Stochastic Oscillator | 25.25 | 74.29 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.